Inflammatory myopathies

Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil

Semin Arthritis RheumPublished Retrospective cohort study

Authors' conclusion

This study found that ulcerative rash in anti-MDA5 DM may not be associated with RP-ILD. The results also suggest that tadalafil may be a useful therapy for refractory cutaneous ulcers.

Study context

Population
Consecutive dermatomyositis (DM) patients with anti-MDA5 antibody62 (75.6 %) female
Participants
82 patients
Exposure
Anti-MDA5 DM with cutaneous ulcers vs without skin ulcers; tadalafil added for refractory cutaneous ulcers
  • Ulcern = 26
  • Refractory ulcers + tadalafiln = 10
Outcome
Features of ulcer vs non-ulcer patients (univariate)
Methodological detailsconsecutive cases, univariate analysis
  • Consecutive cases
  • Univariate analysis

Main finding

As reported in the abstract

Ulcer

31.7 %

26

Gottron's sign more frequent in ulcer patients
P = 0.026
Perlungual erythematosus more frequent in ulcer patients
P = 0.007
Arthritis more frequent in ulcer patients
P = 0.031
Shortness of breath after exercise more likely in non-skin ulcer patients
P = 0.027
Rapidly progressive ILD (RP-ILD) more likely in non-skin ulcer patients
P = 0.024

Observational data: associations, not effects.

Further findings

Improvement in physician global assessment (PGA), CDASI and p-VAS after tadalafil added (refractory ulcers) · within one to two months — Refractory ulcers + tadalafil
80 %
Improvement in PGA, CDASI and p-VAS after tadalafil added (refractory ulcers) — Refractory cutaneous ulcers completely resolved after treatment (patients)
5

Interstitial lung disease (ILD) and RP-ILD in anti-MDA5 DM

%

ILD
95.0
RP-ILD
45.1
  • Approximately

Original publication

Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil. Semin Arthritis Rheum. Published 31 January 2025. doi:10.1016/j.semarthrit.2025.152651

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.